SCHEMBL383250

SCHEMBL383250

N[C@@H]1CNC(=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL383251 1.00
SCHEMBL8282228 1.00
Hydrochloric Acid SCHEMBL1583894 0.97
Hydrochloric Acid SCHEMBL22659777 0.97
Hydrochloric Acid SCHEMBL1695525 0.97
SCHEMBL31277849 0.79
SCHEMBL31681246 0.77 CRBN (0.38)
SCHEMBL4995896 0.74
SCHEMBL384949 0.74
SCHEMBL187229 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724430-A1 CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE Flagship Pioneering Innovations VI, LLC (US) 2026-04-15 EP disclosed
EP-4045037-B1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX INC (US) 2026-01-28 EP disclosed
US-12533354-B2 Triaryl compounds for treatment of PD-L1 diseases CHEMOCENTRYX, INC. (US) 2026-01-27 US disclosed
US-20250346598-A1 HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES CHEMOCENTRYX, INC. (US) 2025-11-13 US disclosed
US-12454524-B2 (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias TERNS PHARMACEUTICALS, INC. (US) 2025-10-28 US disclosed
US-20250276961-A1 COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS Terns, Inc. 2025-09-04 US disclosed
US-20250243184-A1 COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS Terns, Inc. 2025-07-31 US disclosed
US-12371433-B2 Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases AMGEN INC. (US) 2025-07-29 US disclosed
CN-115448908-B Compounds for the treatment of specific leukemias 拓臻股份有限公司 2025-04-25 CN disclosed
CN-115215838-B Compounds for the treatment of specific leukemias 拓臻股份有限公司 2025-04-04 CN disclosed
CN-101142215-A Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith SIGNAL PHARM LLC (US) 2008-03-12 CN disclosed
US-20080021048-A1 Methods of treatment and prevention using haloaryl substituted aminopurines SIGNAL PHARMACEUTICALS, LLC 2008-01-24 US disclosed
US-20080021048-A1 Methods of treatment and prevention using haloaryl substituted aminopurines SIGNAL PHARMACEUTICALS, LLC 2008-01-24 US disclosed
US-20080021048-A1 Methods of treatment and prevention using haloaryl substituted aminopurines SIGNAL PHARMACEUTICALS, LLC 2008-01-24 US disclosed
WO-2007127382-A1 HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-11-08 WO disclosed
US-20070060598-A1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2007-03-15 US disclosed
US-20070060598-A1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2007-03-15 US disclosed
US-20070060598-A1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2007-03-15 US disclosed
US-20060287344-A1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith PHARMACOPEIA, LLC 2006-12-21 US disclosed
WO-2006076595-A1 HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2006-07-20 WO disclosed